Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking

Lung Cancer. 2003 Mar;39(3):297-301. doi: 10.1016/s0169-5002(02)00509-3.


Abnormalities of p53 gene can lead to the production of p53 antibodies (p53-Abs) in the serum of cancer patients. This study was designed to investigate the prevalence of p53-Abs in 133 lung cancer patients and the distribution of these antibodies to clinicopathologic features and smoking status. Twenty five (18.8%) lung cancer patients were found to have p53-Abs. The presence of p53-Abs did not correlate with sex or age but showed frequent association with tumors of squamous cell carcinoma (31%) in comparison with adenocarcinoma (13.6%) (P=0.052). There was a statistically significant difference in the incidence of p53-Abs between early disease group (stage I-II) and the advanced group (stage III-IV) (P=0.036), however, there was no relationship between the presence of p53-Abs and overall survival. Interestingly, the frequent of p53-Abs was higher in smokers (27.1%) than in non-smokers (13.6%), though the difference was of borderline of statistical significance (P=0.061). These findings suggested that p53-Abs could be a potential biomarker for the study of individual with lung cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / etiology
  • Adenocarcinoma / pathology*
  • Aged
  • Antibodies / analysis
  • Carcinoma, Non-Small-Cell Lung / etiology
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Carcinoma, Squamous Cell / etiology
  • Carcinoma, Squamous Cell / pathology*
  • Female
  • Humans
  • Lung Neoplasms / etiology
  • Lung Neoplasms / pathology*
  • Male
  • Middle Aged
  • Prognosis
  • Smoking / adverse effects*
  • Survival
  • Tumor Suppressor Protein p53 / immunology*


  • Antibodies
  • Tumor Suppressor Protein p53